Summary
Global Markets Direct’s, ‘Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H1 2016’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) targeted pipeline therapeutics.
The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Apogenix GmbH
BioInvent International AB
Pfizer Inc.
Pieris Pharmaceuticals, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) Overview 6
Therapeutics Development 7
Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Products under Development by Stage of Development 7
Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Products under Development by Therapy Area 8
Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Products under Development by Indication 9
Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Products Glance 10
Early Stage Products 10
Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Products under Development by Companies 11
Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Products under Development by Universities/Institutes 13
Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 19
Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Companies Involved in Therapeutics Development 21
Apogenix GmbH 21
BioInvent International AB 22
Pfizer Inc. 23
Pieris Pharmaceuticals, Inc. 24
Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Drug Profiles 25
Aptamer to Antagonize CD137 for Oncology - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Monoclonal Antibodies to Agonize 41BB for Oncology - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
PRS-342 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
PRS-343 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Recombinant Protein to Agonize CD137 for Solid Tumor - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Ultra-41BBL - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
utomilumab - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Dormant Projects 34
Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Featured News & Press Releases 35
Mar 17, 2016: Pieris Pharmaceuticals Announces Presentation of In Vivo Preclinical Data for Its Lead Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2016 Annual Meeting of the American Association for Cancer Research (AACR) 35
Nov 06, 2015: Pieris Pharmaceuticals Presents Data at SITC Conference on Lead Immuno-Oncology Program Demonstrating Selective Tumor-Targeted Immune Responses 35
Sep 21, 2015: Pieris Pharmaceuticals Presents Positive Preclinical Data on Lead Bispecific Immuno-Oncology Program 36
May 13, 2015: MorphoSys To Present Data On PF-05082566 at American Society of Clinical Oncology Annual Meeting 36
Dec 22, 2014: MorphoSys Announces Clinical Milestone in Oncology Program 37
Dec 22, 2003: MorphoSys Forges Therapeutic Antibody Collaboration With Pfizer 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39
List of Tables
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Assessment by Monotherapy/Combination Products, H1 2016 15
Number of Products by Stage and Mechanism of Action, H1 2016 17
Number of Products by Stage and Route of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 20
Pipeline by Apogenix GmbH, H1 2016 21
Pipeline by BioInvent International AB, H1 2016 22
Pipeline by Pfizer Inc., H1 2016 23
Pipeline by Pieris Pharmaceuticals, Inc., H1 2016 24
Dormant Projects, H1 2016 34
List of Figures
Number of Products under Development for, H1 2016 7
Number of Products under Development by Top 10 Indication, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 10
Assessment by Monotherapy/Combination Products, H1 2016 15
Number of Products by Mechanism of Actions, H1 2016 16
Number of Products by Stage and Mechanism of Actions, H1 2016 16
Number of Products by Molecule Types, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 19
